Weight reduction of at least 10 percent occurred in 46 to 75 percent receiving orforglipron by week 36
Increased risks included heart failure, cystitis, glucose dysregulation, iron deficiency anemia, poisoning, self-harm
This year's report looked at women's health for the first time and also found pronounced disparities by state in access to prenatal care